Skip to main content

Table 3 Results of regression models: Association of AATD and AT with annual direct and indirect costs

From: Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients

 

Direct costs

Indirect costs

Costs

 

Total direct costs

Outpatient costs

Inpatient costs

Medication costs

Other costs

HC

FC

Group

A

Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

B1

0.95 (0.80 – 1.12)

2.73 (2.35 – 3.17)

0.65 (0.45 – 0.94)

0.90 (0.79 – 1.03)

1.14 (0.81 – 1.61)

1.05 (0.79 – 1.39)

0.94 (0.66 – 1.35)

B2

0.80 (0.57 – 1.13)

1.13 (0.84 – 1.51)

0.79 (0.39 – 1.63)

0.72 (0.56 – 0.93)

1.23 (0.65 – 2.34)

0.67 (0.38 – 1.18)

1.18 (0.67 – 2.08)

  1. A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without AT
  2. Indirect costs only include patients < 65 years of age
  3. Significant estimates on a level of p < .05 are printed bold
  4. Other costs include Physiotherapist and Rehabilitation costs
  5. HC Human capital approach, FC Friction costs approach
  6. Total direct costs and medication costs do not include AT costs of approximately €72,000
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us